180 related articles for article (PubMed ID: 16251803)
1. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.
Smith AP; Hoek K; Becker D
Cancer Biol Ther; 2005 Sep; 4(9):1018-29. PubMed ID: 16251803
[TBL] [Abstract][Full Text] [Related]
2. Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma.
Yang P; Farkas DL; Kirkwood JM; Abernethy JL; Edington HD; Becker D
Mol Med; 1999 Dec; 5(12):785-94. PubMed ID: 10666478
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activity and expression of apoptosis and anti-apoptosis regulators in the progression pathway of human melanoma.
Yang P; Becker D
Int J Oncol; 2000 Nov; 17(5):913-9. PubMed ID: 11029492
[TBL] [Abstract][Full Text] [Related]
4. The gene expression signatures of melanoma progression.
Haqq C; Nosrati M; Sudilovsky D; Crothers J; Khodabakhsh D; Pulliam BL; Federman S; Miller JR; Allen RE; Singer MI; Leong SP; Ljung BM; Sagebiel RW; Kashani-Sabet M
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6092-7. PubMed ID: 15833814
[TBL] [Abstract][Full Text] [Related]
5. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.
Albino AP; Nanus DM; Mentle IR; Cordon-Cardo C; McNutt NS; Bressler J; Andreeff M
Oncogene; 1989 Nov; 4(11):1363-74. PubMed ID: 2682463
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas.
Cowan JM; Halaban R; Francke U
J Natl Cancer Inst; 1988 Sep; 80(14):1159-64. PubMed ID: 3166071
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi.
Gerami P; Wass A; Mafee M; Fang Y; Pulitzer MP; Busam KJ
Am J Surg Pathol; 2009 Dec; 33(12):1783-8. PubMed ID: 19809275
[TBL] [Abstract][Full Text] [Related]
8. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
9. Comparative genome hybridization analysis of laser-capture microdissected in situ melanoma.
Vincek V; Xu S; Fan YS
J Cutan Pathol; 2010 Jan; 37(1):3-7. PubMed ID: 19522846
[TBL] [Abstract][Full Text] [Related]
10. cDNA-array profiling of melanomas and paired melanocyte cultures.
Mischiati C; Natali PG; Sereni A; Sibilio L; Giorda E; Cappellacci S; Nicotra MR; Mariani G; Di Filippo F; Catricalà C; Gambari R; Grammatico P; Giacomini P
J Cell Physiol; 2006 Jun; 207(3):697-705. PubMed ID: 16523488
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
[TBL] [Abstract][Full Text] [Related]
12. Nestin is highly expressed in advanced-stage melanomas and neurotized nevi.
Akiyama M; Matsuda Y; Ishiwata T; Naito Z; Kawana S
Oncol Rep; 2013 Apr; 29(4):1595-9. PubMed ID: 23417116
[TBL] [Abstract][Full Text] [Related]
13. SAGE identification and fluorescence imaging analysis of genes and transcripts in melanomas and precursor lesions.
Smith AP; Weeraratna AT; Spears JR; Meltzer PS; Becker D
Cancer Biol Ther; 2004 Jan; 3(1):104-9. PubMed ID: 14726694
[TBL] [Abstract][Full Text] [Related]
14. TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
Yin M; Soikkeli J; Jahkola T; Virolainen S; Saksela O; Hölttä E
Am J Pathol; 2012 Dec; 181(6):2202-16. PubMed ID: 23063511
[TBL] [Abstract][Full Text] [Related]
15. Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice.
Danen EH; Jansen KF; Van Kraats AA; Cornelissen IM; Ruiter DJ; Van Muijen GN
Int J Cancer; 1995 May; 61(4):491-6. PubMed ID: 7538977
[TBL] [Abstract][Full Text] [Related]
16. Cell adhesion and communication proteins are differentially expressed in melanoma progression model.
Rezze GG; Fregnani JH; Duprat J; Landman G
Hum Pathol; 2011 Mar; 42(3):409-18. PubMed ID: 21193224
[TBL] [Abstract][Full Text] [Related]
17. Melanocytic nevi and tumor progression: perspectives concerning histomorphology, melanoma risk and molecular genetics.
Barnhill RL
Dermatology; 1993; 187(2):86-90. PubMed ID: 8358111
[TBL] [Abstract][Full Text] [Related]
18. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
[TBL] [Abstract][Full Text] [Related]
19. Altered molecular pathways in melanocytic lesions.
Scatolini M; Grand MM; Grosso E; Venesio T; Pisacane A; Balsamo A; Sirovich R; Risio M; Chiorino G
Int J Cancer; 2010 Apr; 126(8):1869-1881. PubMed ID: 19795447
[TBL] [Abstract][Full Text] [Related]
20. Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.
Eriksson J; Le Joncour V; Nummela P; Jahkola T; Virolainen S; Laakkonen P; Saksela O; Hölttä E
Oncotarget; 2016 Mar; 7(12):15065-92. PubMed ID: 26918341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
